Bidding war wont start for long time, companies are no longer taking risk on start up companies, yes elite has a lot going for them selves right now but not to seek billions, so until approval we will stay at the pps where at right now
NASDAQ Elite has already "run the numbers". Nasrat already has an idea of what each opioid is worth. Those numbers he threw out there a couple of years ago were conservative at best. shares outstanding are not much more than they were back when he made that statement.
If each ADT/ART opioid is worth between $4-$5 per share then I highly doubt that Elite will sell itself for cheap. The ADT/ART opioids will vary so lets even become more conservative. Say $3 per share. Times just 7 opioids about $21 per share. Now add in all of Elites IP and assets such as generics and non generic.
$21 per share. I would take that offer but nothing less. With 10 more opioids and a plethora of other applications for their two bead technology..... That would be my bottom figure.
Nasrat has the experience to know what the average value of each ADT/ART is. He has been in the business for what? 30 years?
Yeah NASDAQ, it has the chance to be some real fun for us longs.
Market Data 
Markets 
